Antibody response to synthetic encephalitogenic peptide.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to H C Rauch.
Explore the source record for details and available documents.
An axonally localized, non-encephalitogenic protein derived from bovine spinal cord can protect guinea pigs from EAE following challenge with bovine myelin basic protein. Protection from neurologic signs is significant although CNS pathology is present. The protective regimen apparently varies depending upon the species and strain of animal; this specific requirement may account for a previous negative report.
Treatment with rabbit anti-moneky thymus cell sera whether limited (3 days) or extensive (15 days), did not alter the development of experimental allergic encephalomyelitis (EAE) in rhesus monkeys challenged with myelin basic protein or central nervous system tissue (CNS) when compared to similarly challenged control monkeys treated with normal rabbit serum. No consistent difference in disease incidence or intensity as measured by incubation period, neurologic signs or CNS pathology was observed between experimental and control monkeys. This finding is in contrast to previous reports on the efficacy of ATS treatment in prevention of EAE in rodents.
Multiple sclerosis (MS) patients and normal subjects were tested for cellular hypersensitivity, using the leukocyte migration inhibition test LMI), to a parainfluenza-1-virus (6/94), previously isolated from brain biopsy tissue of an MS patient. The response of MS patients as a group was not greater than that of normals to 6/94, but a significant increase in the response was observed among selected patients in the early active and chronic advanced stages of the disease. MS patients, however, did not differ from normal subjects in their cell response to Sendai virus, a similar parainfluenza type 1 virion used for comparison.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.